an emerging understanding ofthe human footprint and the
impact on the environment has led to the development of
alternatives to classical palladium mediated cross-coupling
reactions. CÀH activation has emerged as a method to
circumvent the requirement of prefunctionalization of the
organometallic components.6,7 Therefore, the ability to
perform multiple CÀH activation reactions on a substrate
using a single set of reaction conditions to prepare densely
functionalized heteroaromatics would greatly facilitate
library synthesis that is important for drug discovery.
Despite the many advantages of CÀH activation, lim-
itations arise when more than one activated hydrogen is
available, which leads to selectivity issues. As an example,
when 3-methyl thiophene undergoes CÀH activation under
palladium catalysis conditions (Scheme 1, conditions a)
with an aryl-bromide, a mixture of C2-arylation (2, R =
Me) and C5-arylation (3, R = Me) in a 3.3 to 1 ratio is
obtained.8 Doucet provided a solution to this issue by
manipulating the C3-susbstituent to favor either C2- or
C5-arylation. He demonstrated that employing an alde-
hyde at the C3-position (1, R = CHO) improves the
selectivity for C2-arylation (Scheme 1, conditions b, ratio
of 2:3 = 81:19, R = CHO). The selectivity could be
reversed by increasing the steric bulk at C3 and converting
the aldehydes to the corresponding acetal (R = CH(OEt2)
to obtain C5ÀH activation as the major product (ratio of
3:2 = 24:76, R = CH(OEt)2) (Scheme 1, conditions b).9
Although an improvement in selectivity was achieved, a
mixture of products was obtained in all cases and isolated
yields of the desired isomer were modest.
simultaneously. The masked carboxylic acid group would
direct intramolecular C4ÀH activation while also allowing
exclusive intermolecular arylation at C5. The Itami group
has demonstrated elegant conditions to selectively arylate
the C4-position of thiophenes;11 however our route re-
quired conditions that would allow both C4 and C5
arylation to occur simultaneously. The carboxylic acid
could then be unmasked providing a synthetic handle for
further functionalization.8,12,13 To our knowledge, only
one synthesis of these biologically important compounds
has been reported by the group of Bogza, which required
the heating of an advanced intermediate under harsh
acidic conditions at elevated temperatures for an extended
period of time.14
Scheme 2. Proposed Route towards Thienoisoquinolines
Our modular synthesis begins with a commercially
available thiophene (8) which was functionalized with a
variety of sulfonyl chlorides resulting in the corresponding
sulfonamides. These sulfonamides were subsequently ben-
zylated in good to excellent yields over two steps giving rise
to the functionalized key intermediates (4) (Table 1).
Benzyl-sulfonamides (4aÀg) were then subjected to
double CÀH activation conditions with a variety of
aryl-bromides (Table 2). Rewardingly, this double
Scheme 1. C2- vs C5-Arylation
During our efforts to prepare thienoisoquinoline inhi-
bitors of estrogen receptor NFκB,10 we proposed a double
arylation (Scheme 2) of an advanced intermediate (4) to
streamline the synthesis of these densely functionalized
heteroaromatics. To prepare these highly functionalized
thienoisoquinolines and circumvent the limitation of CÀH
activation selectivity, we envisioned employing a car-
boxylic acid derivative at the C2-position that allows
for a single set of conditions to undertake both C4-
intramolecular arylation and C5-intermolecular arylation
(11) Ueda, K.; Yanagisawa, S.; Yamaguchi, J.; Itami, K. Angew.
Chem., Int. Ed. 2010, 49, 8946.
(12) For a recent review, see: Cornella, J.; Larrosa, I. Synthesis 2012,
44, 653.
(13) For selected examples: (a) Gooßen, L. J.; Zimmermann, B.;
Knauber, T. Angew. Chem., Int. Ed. 2008, 47, 7103. (b) Goossen, L. J.;
Rodrıguez, N.; Lange, P. P.; Linder, C. Angew. Chem., Int. Ed. 2010, 49,
1111. (c) Lange, P. P.; Goossen, L. J.; Podmore, P.; Underwood, T.;
Sciammetta, N. Chem. Commun. 2011, 47, 3628. (d) Goossen, L. J.;
Linder, C.; Rodrıguez, N.; Lange, P. P. Chem.;Eur. J. 2009, 15, 9336.
(e) Goossen, L. J.; Lange, P. P.; Rodrıguez, N.; Linder, C. Chem.;Eur.
J. 2010, 16, 3906. (f) Goossen, L. J.; Rodrıguez, N.; Melzer, B.; Linder,
C.; Deng, G.; Levy, L. M. J. Am. Chem. Soc. 2007, 129, 4824. (g)
Goossen, L. J.; Deng, G.; Levy, L. M. Science 2006, 313, 662. (h)
Tanaka, D.; Romeril, S. P.; Myers, A. G. J. Am. Chem. Soc. 2005,
127, 10323. (i) Myers, A. G.; Tanaka, D.; Mannion, M. R. J. Am. Chem.
Soc. 2002, 124, 11250. (j) Becht, J.-M.; Le Drian, C. Org. Lett. 2008, 10,
3161. (k) Bilodeau, F.; Brochu, M.-C.; Guimond, N.; Thesen, K. H.;
Forgione, P. J. Org. Chem. 2010, 75, 1550. (l) Mitchell, D.; Coppert,
D. M.; Moynihan, H. A.; Lorenz, K. T.; Kissane, M.; McNamara, O. A.;
Maguire, A. R. Org. Process Res. Dev. 2011, 15, 981.
(7) For selected reviews: (a) Newhouse, T.; Baran, P. S. Angew.
Chem., Int. Ed. 2011, 50, 3362. (b) Ackermann, L.; Vincente, R.; Kapdi,
A. R. Angew. Chem., Int. Ed. 2009, 48, 9792. (c) Chen, X.; Engle, K. M.;
Wang, D.-H.; Yu, J.-Q. Angew. Chem., Int. Ed. 2009, 48, 5094.
(8) Forgione, P.; Brochu, M.-C.; St-Onge, M.; Thesen, K. H.; Bailey,
M. D.; Bilodeau, F. J. Am. Chem. Soc. 2006, 128, 11351.
(9) Dong, J. J.; Doucet, H. Eur. J. Org. Chem. 2010, 611.
(10) Coghlan, R. D.; Fobare, W. F.; Trybulski, E. J. Thienoisoquino-
line-Phenylsulfonamides and Their Use as ER-NFkappaB Inhibitors,
U.S. 2006/0154875, Wyeth (2006).
(14) Zinchenko, S. Y.; Efimenko, R. A.; Suikov, S. Y.; Kobrakov,
K. I.; Bogza, S. L. Chem. Heterocycl. Compd. 2009, 45, 365.
Org. Lett., Vol. 14, No. 11, 2012
2739